COVID-19-Vaccine Market as a New Segment of the Global Vaccine Market
Open Access
- 13 August 2021
- journal article
- Published by Kemerovo State University in Bulletin of Kemerovo State University. Series: Political, Sociological and Economic sciences
- Vol. 2021 (2)
- https://doi.org/10.21603/2500-3372-2021-6-2-178-190
Abstract
The vaccine market is one of the most attractive and fast-growing segments of the global pharmaceutical market. The increasing interest in the development and creation of new vaccines caused a significant influx of investment in research activities, which did not slow down the impact on the further development of the market. The present research featured the global market for COVID-19 vaccines. The research objective was to assess the state of the COVID vaccine market as a new segment of the global vaccine market. The work uses statistical materials of the World Health Organization, the International Federation of Pharmaceutical Manufacturers and Associations, Statista, Rosstat, and Rospotrebnadzor, as well as methods of general logical, analytical, statistical, and empirical analyses. The demands for the global COVID-19 vaccine market are currently enormous, and the global demand for COVID-19 vaccines can range from 10 to 14 billion doses per year, depending on the desired level of coverage and the need for re-vaccination. The current leading manufacturers of vaccines against COVID-19 are Pfizer (USA) / BioNTech (Germany), Sinovac Biotech (China), AstraZeneca (UK), Moderna (USA), and Sinopharm (China). In terms of production volumes, they are significantly inferior to N. F. Gamaleya Federal Research Center for Epidemiology and Microbiology (Russia). The prevalence of World Health Organization-approved vaccines differs by country: (1) Vaxzevria vaccine (AstraZeneca) was approved in 101 countries, (2) Pfizer / BioNTech – in 85 countries, (3) Moderna – in 46 countries, (4) Sinopharm vaccines – 42 countries, (5) Janssen (Johnson & Johnson) – in 41 countries, (6) Covishield (Serum Institute of India) – in 40 countries. As of May 20, 2021, the Russian Sputnik V was registered in 68 countries. For all manufacturers, the expansion of production provokes the same problems, which are mostly connected with the supply of culture media, filters, disposable consumables, and equipment, especially during peak demand.Keywords
This publication has 17 references indexed in Scilit:
- When politics collides with public health: COVID-19 vaccine country of origin and vaccination acceptance in BrazilVaccine, 2021
- The dawn of mRNA vaccines: The COVID-19 caseJournal of Controlled Release, 2021
- COVID-19 vaccine challenges: What have we learned so far and what remains to be done?Health Policy, 2021
- Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deploymentThe Lancet, 2021
- Current progress and challenges in the design and development of a successful COVID-19 vaccineFundamental Research, 2021
- Impact of virus genetic variability and host immunity for the success of COVID-19 vaccinesBiomedicine & Pharmacotherapy, 2021
- The find of COVID-19 vaccine: Challenges and opportunitiesJournal of Infection and Public Health, 2020
- The granting of emergency use designation to COVID-19 candidate vaccines: implications for COVID-19 vaccine trialsThe Lancet Infectious Diseases, 2020
- COVID-19 vaccine: A recent update in pipeline vaccines, their design and development strategiesEuropean Journal of Pharmacology, 2020
- Indirect, out-of-pocket and medical costs from influenza-related illness in young childrenVaccine, 2012